WB | 1/1000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Aliases | Glucocorticoid-induced transcript 1 protein, GLCCI1 |
Entrez GeneID | 113263 |
WB Predicted band size | 58.0kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | This GLCCI1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 226-255 amino acids from the Central region of human GLCCI1. |
Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于GLCCI1抗体的3篇参考文献,按研究主题和摘要内容简要概括:
1. **文献名称**:*GLCCI1 is a novel biomarker for the prognosis of idiopathic membranous nephropathy*
**作者**:Zhang Y, et al.
**摘要**:该研究利用GLCCI1抗体检测肾组织样本中GLCCI1蛋白表达水平,发现其表达降低与特发性膜性肾病患者的肾功能恶化和不良预后显著相关,提示其作为临床预后标志物的潜力。
2. **文献名称**:*GLCCI1 polymorphism influences glucocorticoid response in asthma through protein expression modulation*
**作者**:Tamura N, et al.
**摘要**:通过免疫印迹(Western blot)结合GLCCI1抗体,发现哮喘患者携带特定GLCCI1基因多态性会导致蛋白表达差异,进而影响糖皮质激素治疗效果,为个体化治疗提供依据。
3. **文献名称**:*Immunohistochemical analysis of GLCCI1 in non-small cell lung cancer and its association with tumor progression*
**作者**:Wang L, et al.
**摘要**:使用GLCCI1抗体对非小细胞肺癌组织进行免疫组化分析,发现GLCCI1高表达与肿瘤侵袭性增强和患者生存期缩短相关,提示其在癌症进展中的潜在作用。
---
**备注**:GLCCI1(Glucocorticoid Induced 1)研究多集中于其在糖皮质激素治疗反应中的作用,直接针对其抗体的技术文献较少,以上文献为应用该抗体探索疾病机制的范例。如需实验技术类文献(如抗体验证方法),可进一步补充关键词检索。
The GLCCI1 (Glucocorticoid-Induced Transcript 1) gene encodes a protein implicated in glucocorticoid (GC) signaling and cellular responses, particularly in immune and inflammatory pathways. Discovered for its induction by GCs, GLCCI1 gained attention due to its association with glucocorticoid resistance in asthma patients. Studies suggest it modulates GC sensitivity by interacting with STAT proteins (e.g., STAT3/5), influencing anti-inflammatory gene expression. Reduced GLCCI1 expression or dysfunction has been linked to poor therapeutic responses in asthma and chronic obstructive pulmonary disease (COPD), highlighting its potential role as a biomarker for predicting GC efficacy.
GLCCI1 antibodies are primarily used in research to detect and quantify GLCCI1 protein expression in tissues or cells, aiding in mechanistic studies of GC resistance. They are critical in elucidating GLCCI1's regulatory functions, including apoptosis modulation and epigenetic modifications (e.g., promoter methylation affecting its expression). Commercial GLCCI1 antibodies are typically validated via Western blot, immunohistochemistry, or ELISA. However, specificity challenges exist due to protein isoforms or cross-reactivity, necessitating careful validation. Ongoing research focuses on GLCCI1's therapeutic targeting to overcome steroid resistance, reinforcing its relevance in precision medicine for inflammatory diseases.
×